M&A Earnouts, Risk Allocation, and Post-Closing Incentive Conflicts

Key Takeaways

• Delaware Supreme Court limits implied covenant in earnout disputes
• Earnouts represent about 25% of total M&A transaction value 2020‑2025
• Average earnout transaction grew from $173 M (2024) to $266 M (2025)
• Healthcare and technology deals use earnouts to bridge regulatory and R&D uncertainty
• In deals under $10 M, earnouts can comprise nearly 40% of consideration

Pulse Analysis

Earnouts have become a cornerstone of M&A strategy, particularly for private companies in sectors where future performance hinges on regulatory clearance or breakthrough R&D. Recent analysis of deals from 2020 through 2025 shows that roughly 25% of total transaction value is tied to contingent payments, and the average earnout‑driven deal grew from $173 million to $266 million in a single year. This upward trajectory reflects both the appetite for risk‑sharing and the difficulty of pinning down a definitive valuation when outcomes are uncertain. The J&J v. Fortis decision serves as a judicial reminder that the parties’ original risk allocation survives even when unforeseen regulatory pathways disappear.

The allure of earnouts masks a complex web of incentive conflicts that can erupt after closing. While buyers gain operational control, sellers retain financial exposure, creating a natural tension: buyers may be tempted to under‑invest or alter integration plans to avoid payouts, whereas sellers may push for short‑term metric optimization at the expense of long‑term value. Disputes often center on the measurement of performance—expense timing, revenue recognition, and accounting adjustments can swing earnout calculations dramatically. The Delaware ruling emphasizes that such disputes must be resolved within the strict confines of the agreement, underscoring the need for precise definitions and robust audit rights.

For practitioners, the implications are clear: earnout clauses must be drafted with granular performance metrics, explicit accounting methods, and pre‑agreed dispute‑resolution procedures. Including carve‑outs for regulatory changes, clear governance over post‑closing operational decisions, and mechanisms such as independent third‑party audits can mitigate conflict risk. As the market continues to rely on earnouts to bridge valuation gaps, especially in high‑growth tech and healthcare deals, sophisticated structuring will be essential to balance risk allocation with alignment of post‑closing incentives.